The illicit opioid supply does not evolve in a straight line. When governments restrict one group of synthetic opioids, manufacturers may shift toward a different chemical structure that is less familiar to regulators, laboratories, clinicians, and the public.
That pattern may now be unfolding with cychlorphine, an emerging synthetic opioid in a class commonly called orphines.
After China placed nitazene analogues under generic control in July 2025, forensic laboratories began reporting declining nitazene positivity alongside an increase in orphine analogues, led largely by cychlorphine. However, this does not mean that nitazenes have disappeared or that cychlorphine has completely replaced them. Current evidence points toward a more complicated drug supply in which fentanyl, nitazenes, orphines, benzodiazepines, stimulants, and veterinary sedatives may appear together.
The most accurate answer is that orphines appear to be emerging as a possible successor class within some synthetic-opioid markets, while also becoming another dangerous addition to an already unpredictable supply.
Cychlorphine at a Glance
| Question | Current Information |
|---|---|
| Full name | N-propionitrile chlorphine |
| Drug class | Orphine analogue, or piperidine benzimidazolone opioid |
| Is it a nitazene? | No. It is chemically distinct from nitazenes and fentanyl analogues. |
| Medical use | No approved medical use in the United States |
| Estimated potency | Early laboratory findings suggest potency greater than fentanyl, sometimes estimated at approximately ten times fentanyl’s potency. An exact human comparison has not been established. |
| Common forms | Powders, counterfeit tablets and mixtures containing other drugs |
| Standard test-strip detection | Fentanyl and nitazene test strips are not expected to detect it |
| Overdose response | Give naloxone, call 911, support breathing and repeat naloxone according to product instructions if normal breathing does not return |
Cychlorphine was first identified by the Center for Forensic Science Research and Education, or CFSRE, in August 2024 and confirmed with reference material the following month. Detections in fatal overdose investigations increased significantly during late 2025 and early 2026.
What Is Cychlorphine?
Cychlorphine is a laboratory-made opioid more formally known as N-propionitrile chlorphine. It belongs to a family of opioids called piperidine benzimidazolones, brorphine analogues or, more recently, “orphines.”
Although the names can sound similar, cychlorphine is:
- Not a fentanyl analogue
- Not a nitazene
- Not a prescription opioid
- Not approved for medical treatment
- Not reliably identified by routine opioid screening
Cychlorphine activates opioid receptors, including the mu-opioid receptor responsible for many of the effects associated with heroin, fentanyl, oxycodone and other opioids. Activation of this receptor can produce pain relief, euphoria and sedation, but it can also suppress the brain’s ability to regulate breathing.
Preclinical research involving related orphine compounds found strong opioid-receptor activity and significant respiratory depression. Laboratory-based estimates cited by forensic authorities suggest that cychlorphine may be substantially more potent than fentanyl, but there is not yet enough controlled human research to assign it a precise fentanyl-equivalent dose.
This distinction matters. Describing cychlorphine as “ten times stronger than fentanyl” without qualification can imply a level of clinical certainty that does not currently exist. A more accurate statement is that early laboratory findings suggest cychlorphine may be up to approximately ten times as potent as fentanyl under certain testing conditions.
Regardless of the exact ratio, the available overdose and toxicology data establish that it can be dangerous at very small and unpredictable concentrations.
What Are “Orphines”?
Orphines are a developing group of potent synthetic opioids built around benzimidazolone-related chemical structures. International authorities also refer to them as brorphine analogues or benzimidazol-2-ones.
Examples include:
- Brorphine
- Chlorphine
- Cychlorphine
- Spirochlorphine
- Spirobrorphine
- 5,6-dichloro desmethylchlorphine, also called SR-17018
- 5,6-dichloro brorphine, also called SR-14968
The chemical history of these substances traces back to pharmaceutical research conducted during the 1960s and 1970s. Brorphine became the first prominent modern member of the group to appear in recreational drug markets, emerging in Europe around 2019 and in the United States in 2020. It was placed under international control in 2022.
Newer analogues began appearing as authorities and laboratories became better at detecting and controlling brorphine. Cychlorphine is currently the most frequently reported orphine analogue in UN monitoring data.
Cychlorphine vs. Nitazenes vs. Fentanyl
All three groups can cause opioid intoxication and fatal respiratory depression, but they are chemically different.
| Feature | Fentanyl and Its Analogues | Nitazenes | Orphines |
|---|---|---|---|
| General chemical family | Phenylpiperidine opioids | 2-benzylbenzimidazole opioids | Piperidine benzimidazolone opioids |
| Examples | Fentanyl, carfentanil | Isotonitazene, metonitazene, protonitazene | Brorphine, cychlorphine, spirochlorphine |
| Modern illicit-market emergence | Became dominant during the 2010s | Expanded significantly beginning around 2019 | Brorphine appeared around 2019–2020; newer analogues increased in 2024–2026 |
| Main acute danger | Respiratory depression and overdose | Respiratory depression and overdose | Respiratory and cardiovascular depression |
| Detected by standard fentanyl strips | Fentanyl is generally detectable, although some analogues and mixtures may be missed | No | No |
| Detected by nitazene strips | No | Some nitazenes may be detected, depending on the strip and analogue | No |
The word “benzimidazole” appears in descriptions of both nitazenes and orphines, which can create confusion. Nitazenes are generally 2-benzylbenzimidazoles, while orphines such as cychlorphine are piperidine benzimidazolones. That structural difference affects laboratory identification, test-strip sensitivity and how drug laws are written.
It does not make one class safe. Potency and toxicity can vary dramatically between individual substances within each group.
Are Orphines Replacing Nitazenes?
There is meaningful evidence of substitution, but “replacement” is still too absolute.
In July 2025, China introduced generic controls covering nitazene analogues. CFSRE subsequently reported that nitazene positivity declined while orphine positivity increased, with cychlorphine accounting for much of that rise. UNODC has described this as a shift in the synthetic-opioid landscape and noted that the timing is consistent with adaptive substitution within illicit markets.
Several facts prevent researchers from declaring that orphines have fully replaced nitazenes:
First, cychlorphine has been found alongside nitazenes in toxicology cases. The two classes can coexist in the same market and sometimes in the same person.
Second, fentanyl remains deeply embedded in the North American illicit opioid supply. Orphines may be mixed into fentanyl products rather than sold as a clearly identified alternative.
Third, improved testing can make a drug appear to be increasing partly because laboratories have only recently gained the reference standards and analytical methods needed to identify it.
Finally, synthetic-opioid markets are not uniform. A substance may become common in one region or distribution network while remaining uncommon elsewhere.
A more defensible conclusion is:
Orphines are emerging as a potential post-nitazene opioid class in some illicit-market channels, but the larger trend is diversification rather than a clean replacement of one drug by another.
How Widespread Is Cychlorphine?
The earliest confirmed cychlorphine cases were limited, but reports expanded rapidly during 2025 and 2026.
In May 2026, UNODC reported that cychlorphine had been identified in 10 countries, 182 drug seizures and 78 cychlorphine-related postmortem cases. Most deaths involved more than one substance, although forensic investigators have also identified cases in which cychlorphine was the only opioid detected.
A July 2026 DEA notice documented 225 U.S. forensic encounters involving cychlorphine across 19 states. California was among the states reporting an encounter. The notice also described detections involving mixtures of cychlorphine, fentanyl, nitazenes, benzodiazepines, stimulants, xylazine and medetomidine.
California recorded a fatal overdose involving cychlorphine in San Francisco in April 2026. Toxicology also identified a nitazene and benzodiazepines, illustrating how multiple emerging depressants may appear in a single overdose.
The available public sources establish that cychlorphine has entered California’s drug supply. They do not establish a publicly confirmed Palm Springs or Riverside County cluster. Nevertheless, the California detection demonstrates why Southern California providers, families and people exposed to counterfeit pills should be aware of the drug.
Where Is Cychlorphine Being Found?
Cychlorphine is not necessarily being marketed under its own name. UNODC reports indicate that it has appeared in powders, tablets and at least one blotter-paper sample. It has also been identified in counterfeit medications represented as:
- Xanax
- Percocet
- Dilaudid
- OxyContin
Additional detections have involved fentanyl, heroin, cocaine and medetomidine.
This creates risks for people who have no intention of using an extremely potent opioid. A person purchasing what they believe is alprazolam, oxycodone, hydromorphone, cocaine or another substance may unknowingly ingest cychlorphine.
A July 2026 medical case report described a woman in her twenties who believed she had taken alprazolam. She became unresponsive and developed respiratory depression. Emergency personnel administered 6 milligrams of intranasal naloxone, and comprehensive toxicology later identified cychlorphine along with bromazolam and other substances. Her initial opiate and fentanyl urine screens were negative.
That case demonstrates three important points:
- Cychlorphine exposure can occur through a counterfeit benzodiazepine.
- Routine opiate and fentanyl screens can be negative despite opioid poisoning.
- Naloxone can produce a clinical response in a cychlorphine-involved overdose.
Why Is Cychlorphine So Dangerous?
Extremely Small Dosing Errors May Matter
When a drug is active at very low concentrations, minor manufacturing or mixing inconsistencies can become medically significant. Counterfeit pills are not produced under pharmaceutical controls, so two tablets that look identical may contain very different amounts.
People May Not Know They Took an Opioid
Someone who believes they are using cocaine, alprazolam or a prescription-style pain pill may not carry naloxone or recognize opioid overdose symptoms. They may also combine the substance with alcohol or other depressants without understanding the interaction risk.
Common Test Strips May Miss It
Cychlorphine is not expected to react with fentanyl or nitazene test strips. Routine hospital opioid urine screens may also return negative results. Confirmatory identification generally requires advanced techniques such as liquid chromatography with mass spectrometry.
A negative fentanyl strip therefore does not establish that an unregulated pill or powder is opioid-free.
Polysubstance Exposure Complicates Reversal
Naloxone reverses opioid effects, but it does not reverse benzodiazepines, xylazine, medetomidine or alcohol. If cychlorphine is mixed with these substances, naloxone may restore some breathing while the person remains profoundly sedated.
That partial response does not necessarily mean naloxone failed. It may mean that more than one type of central nervous system depressant is present. DEA has warned that cychlorphine-involved overdoses may require several naloxone doses and immediate medical intervention.
What Does a Cychlorphine Overdose Look Like?
Because cychlorphine is an opioid, an overdose may resemble fentanyl, heroin or prescription-opioid poisoning. Warning signs can include:
- Inability to wake the person
- Very slow, shallow or stopped breathing
- Gurgling, choking or unusual snoring sounds
- Blue, gray or discolored lips and fingernails
- Limpness or extreme sedation
- Small, constricted pupils, although pupil size is not always reliable
- Slow heart rate
- Cold or clammy skin
When it is unclear whether someone is experiencing an overdose, the safer response is to treat the situation as an overdose.
Does Naloxone Work on Cychlorphine?
Current evidence supports giving naloxone in every suspected cychlorphine overdose.
Cychlorphine acts at opioid receptors, and a documented human case involved a naloxone-responsive opioid toxidrome. Some animal research involving related orphines found that naloxone did not completely block every measured effect, but those experiments do not establish that naloxone is ineffective as an emergency overdose treatment in humans.
Official health alerts advise responders to be prepared to give additional naloxone doses. The need for repeated dosing may reflect the opioid’s potency, the amount taken or the presence of multiple drugs.
For a suspected overdose:
- Give naloxone immediately.
- Call 911.
- Support breathing with rescue breaths or CPR as appropriate.
- If normal breathing does not return, give another naloxone dose after two to three minutes or according to the product instructions.
- Place the person on their side when they begin breathing to reduce choking risk.
- Stay with them until emergency responders arrive.
Naloxone will not harm someone simply because the emergency turns out not to involve an opioid. Its effects are temporary, so medical evaluation remains necessary even when the person wakes up.
Can Fentanyl Test Strips Detect Cychlorphine?
No. Current fentanyl test strips are not designed to identify cychlorphine or other orphine analogues.
Nitazene test strips are also not expected to identify cychlorphine. An unregulated pill or powder can therefore test negative for fentanyl and nitazenes while still containing an extremely potent opioid.
Drug checking can provide useful information, but no single strip can confirm that a sample is safe. The rapidly changing supply increasingly requires broader laboratory testing capable of detecting multiple novel substances.
Can Cychlorphine Cause Addiction and Withdrawal?
Human research specifically examining cychlorphine dependence and withdrawal remains limited. However, its strong activity at mu-opioid receptors means repeated use would be expected to carry risks associated with other potent opioids, including:
- Increasing tolerance
- Physical dependence
- Cravings
- Compulsive use
- Withdrawal between doses
- Continued use despite serious consequences
- Elevated overdose risk after a period of abstinence
A person does not need to know the exact opioid they have been using before seeking help. Treatment can begin based on symptoms, withdrawal history, overdose history and the clinical signs of opioid use disorder.
Treatment for Cychlorphine and Other Synthetic Opioids
Treatment for cychlorphine exposure follows established principles for opioid use disorder. The precise drug may affect withdrawal timing and medical decisions, but it does not make recovery impossible.
Care may include:
- A medically supervised opioid detox program
- Assessment for co-occurring benzodiazepine, stimulant or alcohol use
- Medication for opioid use disorder when clinically appropriate
- Residential treatment
- Individual and group therapy
- Trauma-informed care
- Relapse-prevention planning
- Naloxone education
- Outpatient and continuing-care support
Buprenorphine, methadone and naltrexone are FDA-approved medications used in the treatment of opioid use disorder. The appropriate medication and timing must be determined individually, especially when the identity and duration of the opioid are uncertain.
Phoenix Rising Recovery provides medical detox, fentanyl and opioid addiction treatment, medication-assisted treatment, residential care and outpatient support in Palm Springs, California. Treatment is designed around the person’s complete pattern of use rather than relying only on a routine drug-screen result.
Begin Opioid Addiction Treatment in Palm Springs
Cychlorphine is another reminder that people cannot reliably identify today’s illicit drug supply by a pill’s imprint, a powder’s appearance or the name used by a seller. Someone may believe they are using a familiar drug while being exposed to an opioid that is more potent, harder to detect and mixed with several additional substances.
Early treatment can interrupt that risk before another overdose occurs.
Phoenix Rising Recovery offers personalized opioid addiction care in Palm Springs, including medical stabilization, medication-assisted treatment, therapy and continuing recovery support. Contact our admissions team or verify your insurance benefits confidentially to learn which level of care may be appropriate.
If someone is currently unresponsive, breathing abnormally or showing other signs of overdose, call 911 and administer naloxone immediately.
Frequently Asked Questions About Cychlorphine and Orphines
Is cychlorphine a nitazene?
No. Cychlorphine and nitazenes are both synthetic opioids, but they belong to different chemical families. Cychlorphine is an orphine, or piperidine benzimidazolone opioid.
Is cychlorphine stronger than fentanyl?
Early laboratory findings suggest that cychlorphine may be more potent than fentanyl and have sometimes been interpreted as indicating approximately ten times fentanyl’s potency. The exact potency in humans has not been established, so the ratio should be treated as an early laboratory estimate rather than a precise clinical conversion.
Are orphines replacing nitazenes?
Orphine detections increased after China introduced generic nitazene controls in July 2025, while nitazene positivity declined in some forensic data. This supports a possible substitution pattern, but nitazenes continue to circulate and have been detected alongside cychlorphine. Orphines are better understood as an emerging addition and possible successor class, not a complete replacement.
Does Narcan work on cychlorphine?
Naloxone, commonly sold as Narcan, should be administered immediately in a suspected cychlorphine overdose. A published human case documented a naloxone-responsive overdose involving cychlorphine. More than one dose may be needed, and emergency medical care is still essential.
Will cychlorphine appear on a standard drug test?
It may not appear on routine hospital opioid or fentanyl screens. Specialized mass-spectrometry testing with updated reference data is generally required to confirm exposure.
Can cychlorphine be found in counterfeit Xanax or pain pills?
Yes. Cychlorphine has been identified in counterfeit tablets represented as Xanax, Percocet, Dilaudid and OxyContin. A published overdose case involved a person who believed she had taken alprazolam.
Can someone recover from cychlorphine addiction?
Yes. Treatment addresses opioid use disorder, withdrawal, overdose risk and any co-occurring substance use or mental health conditions. Medical detox, medications for opioid use disorder, structured treatment and continuing support can all be incorporated into an individualized recovery plan.
Sources
Centers for Disease Control and Prevention. (2024, May 2). 5 things to know about naloxone. https://www.cdc.gov/overdose-prevention/reversing-overdose/about-naloxone.html
Center for Forensic Science Research and Education. (2026, January 30). Increase in fatal overdoses linked to novel synthetic opioid N-propionitrile chlorphine (cychlorphine). https://www.cfsre.org/nps-discovery/public-alerts/increase-in-fatal-overdoses-linked-to-novel-synthetic-opioid-n-propionitrile-chlorphine-cychlorphine
Drug Enforcement Administration. (2026, July 1). Schedules of controlled substances: Temporary placement of 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine in Schedule I of the Controlled Substances Act. Federal Register, 91, 39940–39945. https://www.federalregister.gov/documents/2026/07/01/2026-13364/schedules-of-controlled-substances-temporary-placement-of-56–dichloro-brorphine-56-dichloro
Sprague, J. E., et al. (2026). Non-fatal opioid overdose associated predominantly with the benzimidazolone, cychlorphine. Clinical Toxicology, 64(2), 146–147. https://pubmed.ncbi.nlm.nih.gov/41347459/
United Nations Office on Drugs and Crime. (2026, February 25). Increasing nitazene and orphine analogues (synthetic opioids) and the implications for the use of test strips. https://www.unodc.org/LSS/Announcement/Details/e69b2ff5-5b91-4eea-8e1f-802ca7ad5080
United Nations Office on Drugs and Crime. (2026, May 14). The emerging threat of cychlorphine: A new synthetic opioid raising concerns globally for public health. https://www.unodc.org/LSS/Announcement/Details/9403c3d1-12b9-49ac-8604-7da583d38d3b